NCT06480383
Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 9 versions: 8 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 56 → 59 locations
- Notable Eligibility criteria expanded, about 18 words
- Study completion pushed from Mar 23, 2027 to Oct 21, 2027
- Secondary endpoints: details revised at 1 of 1 entry
- Site details revised at 1 of 56 sites
Notable Eligibility criteria expanded, about 48 wordsv6 Show 4 more changesShow less
- Trial sites reduced: 69 → 56 locations
- Primary completion moved earlier from Jun 2027 to Mar 16, 2027
- Study completion moved earlier from Jun 2027 to Mar 23, 2027
- Study description shortened, about 75 words
- Minor Study sites: 30 to 69v5
- Minor Study sites: 28 to 30v4
Show 2 earlier versionsHide 2 earlier versions
- Minor Study sites: 29 to 28
- Primary and study completion dates pushed to Jun 2027
- Minor Study sites: 27 to 29
- Start date changed from estimate of Jun 2024 to Aug 5, 2024
- Interventions: ITI-1284 10 mg (Drug), ITI-1284 20 mg (Drug), Placbo (Drug) to ITI-1284 10 mg (Drug), ITI-1284 20 mg (Drug), Placebo (Drug)
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Hamilton Anxiety Rating Scale (HAM-A)
Timeframe: Week 6
Secondary (1)
Clinical Global Impression Scale-Severity (CGI-S)
Arms and interventions
ITI-1284 10 mgExperimental
ITI-1284 20 mgExperimental
PlaceboPlacebo comparator
Drugs: ITI-1284 10 mg, ITI-1284 20 mg, Placebo
Sites
59 sites in 6 countries
United States 25, Bulgaria 13, Serbia 7, Poland 6, Czechia 5, Finland 3